Phospholipase A 2 (PLA 2 ) is an enzyme that catalyzes the hydrolysis of membrane glycerophospholipids at the 2 position to produce free fatty acids, in particular arachidonic acid, and lysophospholipids. Among a number of PLA 2 isozymes identified so far, several isozymes including secretory forms are involved in the release of arachidonic acid, a precursor for prostaglandins and leukotrienes. 1) Since the eicosanoids are potent mediators of inflammation, the inhibition of PLA 2 is a prime target for designing new anti-inflammatory agents. [2] [3] [4] [5] [6] [7] In fact, a number of its inhibitors such as varespladib, 8) pyrrophenone, 9) efipladib 10) and methyl indoxam 11) have been reported. N-[2-(Ethanesulfonylamino)-5-trifluoromethyl-3-pyridinyl]cycloalkanecarboxamide (1) having a trifluoromethyl (CF 3 )-pyridine ring was reported to possess a moderate inhibitory activity against pancreatic secretory phospholipase A 2 (sPLA 2 ) in in vitro experiments. 12) Trifluoromethyl-substituted pyridines are useful ring unit 13, 14) and have shown interesting profiles as essential structures in many kinds of biological molecules including agrochemical and medicinal candidates. [15] [16] [17] [18] We have re-investigated the above molecule and attempted to simplify and modify its structure in order to improve the inhibitory activity for PLA 2 ( Fig. 1) .
We have designed new molecules by the following directions; i) removal of the 3-cycloalkanecarboxamide moiety from 1, ii) change of the position of the CF 3 group and introduction of an additional CF 3 group or other electron withdrawing group, iii) replacement of ethanesulfonamide with other alkane-and arenesulfonamides. In this paper, we describe the preparation of compounds 2-5, designed by the above direction, and evaluation of their structure-activity relationships with respect to the inhibiting activity against PLA 2 Group IB (GIB).
The structure of designed compounds are listed in Fig. 2 . We categorized the analogs by 5-trifluoromethyl, 4-trifluoromethyl, 4,5-bis(trifluoromethyl), and 4,6-bis(trifluoromethyl) groups, as compounds, 2a-d, 3a-d, 4a-k, and 5a-f, respectively.
The formation of the amide bond was carried out simply by heating of 2-chloropyridine 6a-f and alkane-or arenesulfonamide 7a-j with K 2 CO 3 in dimethyl sulfoxide (DMSO) at 115-150°C. For example, the reaction of 2-chloro-5-trifluoromethylpyridine (6a) and ethanesulfonamide (7a) (1.5 eq) in DMSO in the presence of K 2 CO 3 (2.5 eq) at 130°C for 2 h gave N-(5-trifluoromethyl-2-pyridinyl)ethanesulfonamide (2a) in 65% yield. Other molecules, with the exception of 4k, were similarly prepared and the results are as shown in Table 1 . The compound 4k was prepared in 85% yield from 3a by the standard nitration.
All new sulfonamides were evaluated for their inhibiting activity against porcine pancreas originated sPLA 2 . The activity was assessed by measuring free fatty acids released from phospholipids, as a substrate, with photometric assay using the acyl-CoA synthetase/acyl-CoA oxidase (ACS-ACO) method. 19) We have screened all the sulfonamides at a fixed concentration (0.5 mM), and some of them were also Table  1 .
If a functional substituent on the pyridine ring was replaced with hydrogen without loss of biological activity, it would reduce the number of synthetic steps. In fact, for the synthesis of compounds 2-5, the synthesis would become much simpler in comparison with that of 1. Replacing the C-3 carboxamide moiety in 1 with hydrogen afforded 5-trifluoromethyl substituted ethanesulfonamide 2a (entry 1), which inhibited sPLA 2 by 4.6%. Compound 3a in which a CF 3 group located at the C-4 position instead of at C-5, inhibited by 20.6%. In comparison of compounds 2a and 3a (entries 1 and 5), in both of which the C-3 position is unsubstituted, the inhibitory activity of 3a exceeded that of 2a, indicating the importance of the CF 3 substituent at the C-4 site. When ethanesulfonamides in 2a and 3a were replaced with benzenesulfonamides gave 2b and 3b, the inhibitory activity enhanced to 15.4% and 25.0% in both cases (entries 2 and 6). The presence of a chloro group at the C-6 position, compounds 2c and 2d (entries 3 and 4) provided inhibitors that were slightly active than compounds 2a and 2b. While, the corresponding 4-trifluoromethyl derivatives 3c and 3d (entries 7 and 8) were less active than 3a and 3b. It is noted that benzenesulfonamides 2b, 2d, 3b and 3d were more potent than ethanesulfonamides 2a, 2c, 3a and 3c, respectively.
Since the CF 3 substituent at C-4 showed a better inhibitory profile than that at C-5, we examined 4,5-bis(trifluoromethyl)pyridine derivatives 4. In the cases of 2a-d and 3a-d, benzenesulfonamides were more potent than ethanesulfonamides. A little but similar trend was observed in 4,5-bis(triflluoromethyl)pyridine derivatives 4a and 4b (entries 9 and 10). N- [4, -2-pyridinyl] ethanesulfonamide (4a) and the corresponding benzenesulfonamide 4b, each at 0.5 mM inhibited PLA 2 GIB by 24.5% and 26.4%, respectively. Other alkanesulfonamides, the respective methyl-, propyl-, and isopropyl analogs, 4c, 4d, and 4e, as well as trifluoromethanesulfonamide 4f (entries [11] [12] [13] [14] , all showed inferior activity than 4a.
Next, we examined the effect of the substituent on the aromatic ring of the arenesulfonamide in the series of N- [4,5- bis(trifluoromethyl)-2-pyridinyl] derivatives. 4-Methoxybenzenesulfonamide 4g (entry 15) was slightly active to compare with the phenyl analogue 4b, while the 4-chloro-, and 4-trifluoromethylbenzenesulfonamides 4h and 4i (entries 16 and 17) were 1.4 fold more active than 4b. 2-Naphtharenesulfonamide 4j (entry 18) was a little less potent than 4h and 4i. Replacement of an electron-withdrawing CF 3 group at the C-5 position with other electron-withdrawing nitro group, in 4k (entry 19), decreased the inhibitory potency by 25%, in comparison to 4a. These results indicated that the 4,5-bis(trifluoromethyl) substituent pattern positively influenced the inhibitory activity. We have also examined 4,6-bis(trifluoromethyl)pyridine derivatives 5. Ethane-and benzenesulfonamides 5a and 5b (entries 20 and 21) showed similar potency as same as 4a and 4b. 4-Methoxy-and 4-trifluoromethylbenzenesulfonamides 5c and 5e (entries 22 and 24) were less active than the corresponding 4g and 4i. However, somehow the 4-chlorobenzenesulfonamide 5d (entry 23) was 1.8-fold less active than 5b. 2-Naphtharenesulfonamide 5f (entry 25) was the most active of the 4,6-bis(trifluoromethyl)pyridine derivatives.
Comparison of the inhibition data between 5-CF 3 , 6-CF 3 , 4,5-bis-CF 3 and 4,6-bis-CF 3 derivatives indicate that the 4,5-bis(trifluoromethyl) as well as 4,6-bis(trifluoromethyl)substituent patterns effectively show better inhibitory activities.
Inhibitory activities of several selected compounds were tested at the 3 mM concentration. These results were consistently supported the results obtained at the 0.5 mM concentration. The IC 50 values for compounds 2d, 4h, 4i, and 5f are listed in Table 1 . Particularly, N- [4,5- 
bis(trifluoromethyl)-2-
pyridinyl]-4-trifluoromethylbenzenesulfonamide 4i exhibited the most potent IC 50 value (at 0.58 mM) in the inhibition of sPLA 2 . Although they are lacking a carboxamide moiety at the C-3 position on the pyridine ring, their activities are almost similar or even better than those of the compounds 1.
12)
In conclusion, we have demonstrated a simple CF 3 -substituted 2-pyridinylarenesulfonamides exhibited an inhibitory activity of sPLA 2 . Although their acivitiy is moderate, N-[bis(trifluoromethyl)-2-pyridinyl]arenesulfonamides 4h, 4i, and 5f showed excellent profile in the inhibition. Particularly, compound 4i was found to be the most potent. It is noted that all these compounds are able to prepare quite easily by a single coupling of 6 with sulfonamide 7.
Experimental
Melting points were determined on a Yanagimoto micro-melting point apparatus and were not corrected.
1 H-NMR spectra were recorded on a JEOL JNM-GSX 400 (400 MHz) or JNM-AL 300 (300 MHz) spectrometers in CDCl 3 or DMSO-d 6 with tetramethylsilane as an internal standard. IR spectra were recorded on JASCO FT/IR-410 instrument. Column chromatography was carried out using Merck silica gel 60 (70-230 mesh).
Typical Reaction for Coupling of 2-Chloropyridines 6a-f and Sulfonamides 7a-j To a mixture of 7 (7.5 mmol) and K 2 CO 3 (1.73 g, 12.5 mmol) in dimethyl sulfoxide (DMSO) (20 ml) was added 6 (5 mmol) in DMSO (2 ml) portionwise at 95°C. The mixture was heated at 115-150°C for 1.5-17 h. After cooling, water (50-100 ml) was added to the reaction mixture, and the mixture was washed with ether. The pH of the aqueous layer was adjusted to a range between 4 to 6 with 2 N hydrochloric acid to form a precipitate, which was collected and recrystallized from a mixture of EtOAc and hexane to give 2-5. When precipitate was not formed, the aqueous layer was extracted with EtOAc (50 mlϫ2), the combined organic layer was washed with brine, dried over Na 2 SO 4 , and condensed. The residual liquid was purified by silica gel column chromatography. For the synthesis of 3c and 3d, reverse addition was taken.
Chemical yields of the products are listed in Table 1 Preparation of N-(5-Nitro-4-trifluoromethyl-2-pyridinyl)ethanesulfonamide (4k) To a stirred solution of 3a (16 mmol) in acetic acid (15 ml) was added dropwise fumic nitric acid (2.1 ml, 48 mmol) at 100°C and the reaction was continued for an additional 2.5 h at 115°C. After cooling the mixture was poured into an ice water (70 ml) to form solid. The solid were collected by filtration, washed with water and dried to give crude product, which was purified by silica gel column chromatography eluted with EtOAc to give 4k as pale yellow solid. mp 201-202°C; Assay of PLA 2 Activity The ability of the synthetic compounds to inhibit sPLA 2 activity was determined in an assay system using a substrate of mixed micelles of phosphatidylcholine and cholate, according to the procedure reported by Volwerk et al. 20) Dipalmitoyl phosphatidylcholine (13.6 mmol) and 0.5 M sodium cholate (120 ml) were suspended in 1880 ml of buffer containing 250 mM NaCl and 250 mM Tris-HCl, pH 8, and used as the substrate. The reaction mixture (total volume of 50 ml) contained (final concentrations) 0.2 mg/ml porcine pancreatic PLA 2 (Sigma-Aldrich), 2.7 mM dipalmitoyl-PC, 12 mM sodium cholate, 10 mM CaCl 2 , 94 mM NaCl, 1 mg/ml bovine serum albumin (BSA), 94 mM Tris-HCl, pH 8, and the test sample at various concentrations. The reaction was started by addition of the substrate to a mixture of PLA 2 and a test sample, and incubation was continued at 37°C for 30 min. The production of free fatty acids was measured by the ACS-ACO method. 19) After the incubation, 50 ml of colorization reagent A (NEFA C-Test Wako; 1.46 mM coenzyme A, 9 mM ATP, 3 mM 4-aminoantipyrine, 0.54 U/ml ACS, 5.4 U/ml ascorbate oxidase, 50 mM phosphonate, pH 7) was added to the reaction mixture and incubation was continued at 37°C for another 10 min. Then 100 ml of colorization reagent B (NEFA C Test Wako; 5.5 U/ml ACO, 6.8 U/ml peroxidase, 1.2 mM 3-methyl-N-ethyl-N-(b-hydroxyethyl)aniline) was added and incubation was continued at 37°C for another 10 min. The production of dye was evaluated by measuring the absorbance at 595 nm. Three replicates were used for each determination of sPLA 2 activity.
